Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALPL | P05186 | 1/20 | 0.40 |
| ▸ | ALPI | P09923 | 1/20 | 0.40 |
| ▸ | ALPG | P10696 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5073228 | 1.00 | CYP2C19 (0.48) | CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5272714 | 0.98 | CYP2C19 (0.50) | CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5979449 | 0.92 | CYP2C19 (0.52) | CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL28131316 | 0.90 | CYP2C19 (0.50) | CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL6306047 | 0.87 | CYP2C19 (0.59) | CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL28965534 | 0.85 | CYP2C19 (0.57) | CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL8748290 | 0.84 | CYP2C19 (0.48) | CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5074208 | 0.84 | CYP1A2 (0.53) | CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL934486 | 0.83 | CYP2C19 (0.55) | CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL7909121 | 0.83 | CYP2C19 (0.59) | CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2414372-B1 | CHEMICAL SYNTHESIS OF PHOSPHATIDYLINOSITOL MANNOSIDE GLYCANS FROM MYCOBACTERIUM TUBERCULOSIS | MAX PLANCK GESELLSCHAFT (DE) | 2013-10-23 | — | — | EP | disclosed |
| US-8536153-B2 | Chemical synthesis of phosphatidylinositol mannoside glycans from Mycobacterium tuberculosis | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2013-09-17 | — | — | US | disclosed |
| EP-2414372-A1 | CHEMICAL SYNTHESIS OF PHOSPHATIDYLINOSITOL MANNOSIDE GLYCANS FROM MYCOBACTERIUM TUBERCULOSIS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2012-02-08 | — | — | EP | disclosed |
| US-20110256173-A1 | CHEMICAL SYNTHESIS OF PHOSPHATIDYLINOSITOL MANNOSIDE GLYCANS FROM MYCOBACTERIUM TUBERCULOSIS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2011-10-20 | — | — | US | disclosed |
| EP-2186818-A1 | Chemical synthesis of phosphatidylinositol mannoside glycans form mycobacterium tuberculosis | ETH Zurich (CH) | 2010-05-19 | — | — | EP | disclosed |
| WO-2010051961-A1 | CHEMICAL SYNTHESIS OF PHOSPHATIDYLINOSITOL MANNOSIDE GLYCANS FROM MYCOBACTERIUM TUBERCULOSIS | ETH ZURICH (CH) | 2010-05-14 | — | — | WO | disclosed |
| US-4393070-A | HYPOTENSIVE, VASODILATION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-07-12 | — | — | US | disclosed |
| US-4307103-A | TREATMENT OF HYPERTENSION AND CARDIOVASCULAR DISEASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110256173-A1 | CHEMICAL SYNTHESIS OF PHOSPHATIDYLINOSITOL MANNOSIDE GLYCANS FROM MYCOBACTERIUM TUBERCULOSIS | PIM1, PIM3, PIM2 | CYP2C19 4325/4885CYP1A2 4003/4885CYP3A4 3016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.